The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.
An endemic coronavirus appears to be the premise that leading Indian firm Cipla Limited is factoring into its business, at least for now, and that in turn could mean a sustained revenue stream for its COVID-19 therapies in the immediate future.
Cipla saw strong growth of its prescription business in India in the second quarter of fiscal 2021, driven by continued traction in its COVID-19 portfolio, with management indicating that more understanding of the virus suggests that it “is going to
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
